Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 — Lincoln, Nebraska

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 is a clinical research site located in Lincoln, Nebraska, United States 68505-2343.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 has participated in 2 clinical trials.

Therapeutic areas: Atopic Dermatitis.

Sponsors: AbbVie.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Lincoln

Browse all research sites in Nebraska · View every site in Lincoln

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548?

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 conducted?

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 has 2 clinical trials on record. Their work covers Atopic Dermatitis.

Is Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 accredited by Crixeo Clinical Trials?

Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.